Generic Name and Formulations:
Bisoprolol (as fumarate), hydrochlorothiazide; 2.5mg/6.25mg, 5mg/6.25mg, 10mg/6.25mg; tabs.
Indications for ZIAC:
Initially one 2.5mg/6.25mg tab once daily. Adjust at 14-day intervals; max two 10mg/6.25mg tabs (20mg bisoprolol + 12.5mg HCTZ) once daily.
Cardiogenic shock. Overt heart failure. 2nd- or 3rd-degree AV block. Marked sinus bradycardia. Anuria. Sulfonamide allergy.
CHF. Peripheral vascular disease. Bronchospastic disease. Surgery. Thyroid disease. Avoid abrupt cessation. Gout. Arrhythmia. SLE. Postsympathectomy. Excessive fluid loss. Monitor electrolytes, BUN (if high). Discontinue if electrolyte disorders develop rapidly. Diabetes. Hepatic or renal impairment. Pregnancy (Cat.C). Nursing mothers: not recommended.
Cardioselective beta-blocker + diuretic.
May potentiate other antihypertensives, reserpine, guanethidine, other catecholamine-depleting drugs, calcium channel blockers, antiarrhythmics, myocardial depressants, nondepolarizing muscle relaxants. Digitalis, lithium toxicity. Antagonized by rifampin, NSAIDs. Increased rebound hypertension with clonidine withdrawal. Adjust antidiabetic, antigout medications. Hyperglycemia, hyperuricemia more likely with diazoxide. NSAIDs may cause renal failure. ACTH, corticosteroids, amphotericin B increase hypokalemia risk. Orthostatic hypotension with alcohol, CNS depressants. May block epinephrine. May interfere with parathyroid tests.
Dizziness, fatigue, cough, insomnia, diarrhea, muscle cramps, impotence.
Tabs 2.5mg/6.25mg, 5mg/6.25mg—100; 10mg/6.25mg—30
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes In on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma